Home LiteratureArticle Details
PMID: 18509178 Published · ppublish English Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Influence of clinical communication on patients' decision making on participation in clinical trials.

Albrecht TL, Eggly SS, Gleason ME, Harper FW, Foster TS, Peterson AM, Orom H, Penner LA, Ruckdeschel JC

Abstract

To investigate how communication among physicians, patients, and family/companions influences patients' decision making about participation in clinical trials. We video recorded 235 outpatient interactions occurring among oncologists, patients, and family/companions (if present) at two comprehensive cancer centers. We combined interaction analysis of the real-time video-recorded observations (collected at Time 1) with patient self-reports (Time 2) to determine how communication about trial offers influenced accrual decisions. Clinical trials were explicitly offered in 20% of the interactions. When offers were made and patients perceived they were offered a trial, 75% of patients assented. Observed messages (at Time 1) directly related to patients' self-reports regarding their decisions (2 weeks later), and how they felt about their decisions and their physicians. Specifically, messages that help build a sense of an alliance (among all parties, including the family/companions), provide support (tangible assistance and reassurance about managing adverse effects), and provide medical content in language that patients and family/companions understand are associated with the patient's decision and decision-making process. In two urban, National Cancer Institute-designated comprehensive cancer centers, a large percentage of patients are not offered trials. When offered a trial, most patients enroll. The quality and quantity of communication occurring among the oncologist, patient, and family/companion when trials are discussed matter in the patient's decision-making process. These findings can help increase physician awareness of the ways that messages and communication behaviors can be observed and evaluated to improve clinical practice and research.

MeSH Terms
Clinical Trials as Topic/psychology Communication Decision Making Female Humans Male Middle Aged Neoplasms/therapy Patient Participation/psychology Physician-Patient Relations
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Albrecht Terrance L
Barbara Ann Karmanos Cancer Institute, 4100 John R St, Detroit, MI 48201, USA. [email protected]
Eggly Susan S
Gleason Marci E J
Harper Felicity W K
Foster Tanina S
Peterson Amy M
Orom Heather
Penner Louis A
Ruckdeschel John C
References (33)
33 references, click to expand
  1. Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis.
    J Clin Oncol. 2005 Feb 20;23(6):1278-88 PMID: 15718326
  2. Physician perspectives on cancer clinical trials and barriers to minority recruitment.
    Cancer Control. 2005 Nov;12 Suppl 2:93-6 PMID: 16327757
  3. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study.
    Gynecol Oncol. 2004 Aug;94(2):368-74 PMID: 15297174
  4. The physician-patient working alliance.
    Patient Educ Couns. 2007 Apr;66(1):29-36 PMID: 17188453
  5. Communication and consumer decision making about cancer clinical trials.
    Patient Educ Couns. 2003 May;50(1):39-42 PMID: 12767583
  6. Altruism as a reason for participation in clinical trials was independently associated with adherence.
    J Clin Epidemiol. 2005 Nov;58(11):1109-14 PMID: 16223653
  7. Factors associated with participation in breast cancer treatment clinical trials.
    J Clin Oncol. 2006 Apr 20;24(12):1860-7 PMID: 16622260
  8. Communication and informed consent.
    Curr Opin Oncol. 2005 Jul;17(4):336-9 PMID: 15933463
  9. Participation in cancer clinical trials: race-, sex-, and age-based disparities.
    JAMA. 2004 Jun 9;291(22):2720-6 PMID: 15187053
  10. Participation of minorities in cancer research: the influence of structural, cultural, and linguistic factors.
    Ann Epidemiol. 2000 Nov;10(8 Suppl):S22-34 PMID: 11189089
  11. Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous.
    J Clin Oncol. 2007 Mar 20;25(9):1148; author reply 1148-9 PMID: 17369584
  12. Strategic physician communication and oncology clinical trials.
    J Clin Oncol. 1999 Oct;17(10):3324-32 PMID: 10506636
  13. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.
    J Clin Oncol. 2002 Apr 15;20(8):2109-17 PMID: 11956272
  14. A portable, unobtrusive device for videorecording clinical interactions.
    Behav Res Methods. 2005 Feb;37(1):165-9 PMID: 16097357
  15. Participation in the RACS sentinel node biopsy versus axillary clearance trial.
    ANZ J Surg. 2005 Mar;75(3):98-100 PMID: 15777382
  16. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.
    J Clin Oncol. 2006 Oct 1;24(28):4545-52 PMID: 17008693
  17. Predictors of enrollment in lung cancer clinical trials.
    Cancer. 2006 Jan 15;106(2):420-5 PMID: 16342295
  18. Clinicians' attitudes to clinical trials of cancer therapy.
    Eur J Cancer. 1997 Nov;33(13):2221-9 PMID: 9470810
  19. Knowledge and access to information on recruitment of underrepresented populations to cancer clinical trials.
    Evid Rep Technol Assess (Summ). 2005 Jun;(122):1-11 PMID: 15989377
  20. Seeking informed consent to cancer clinical trials: describing current practice.
    Soc Sci Med. 2004 Jun;58(12):2445-57 PMID: 15081196
  21. Patient-physician communication concerning participation in cancer chemotherapy trials.
    Br J Cancer. 2004 Jan 26;90(2):328-32 PMID: 14735172
  22. Factors influencing inclusion of patients with malignancies in clinical trials.
    Cancer. 2006 Jan 15;106(2):258-70 PMID: 16397866
  23. Provider roles in the recruitment of underrepresented populations to cancer clinical trials.
    Cancer. 2007 Feb 1;109(3):465-76 PMID: 17200964
  24. Information and decision-making preferences of hospitalized adult cancer patients.
    Soc Sci Med. 1988;27(11):1139-45 PMID: 3206248
  25. Information seeking during "bad news" oncology interactions: Question asking by patients and their companions.
    Soc Sci Med. 2006 Dec;63(11):2974-85 PMID: 16962218
  26. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California.
    Cancer J. 2004 Sep-Oct;10(5):294-300 PMID: 15530258
  27. Reasons for participation and non-participation in a randomized controlled trial: postal questionnaire surveys of women eligible for TOMBOLA (Trial Of Management of Borderline and Other Low-Grade Abnormal smears).
    Clin Trials. 2006;3(5):431-42 PMID: 17060217
  28. Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision.
    J Clin Oncol. 2004 Nov 1;22(21):4312-8 PMID: 15514372
  29. Managing accrual in cooperative group clinical trials.
    J Clin Oncol. 2004 Aug 1;22(15):2997-3002 PMID: 15284251
  30. Patients' decision-making process regarding participation in phase I oncology research.
    J Clin Oncol. 2006 Sep 20;24(27):4479-84 PMID: 16983117
  31. Understanding patient decisions about clinical trials and the associated communication process: a preliminary report.
    J Cancer Educ. 2003 Winter;18(4):210-4 PMID: 14766331
  32. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001.
    J Clin Oncol. 2005 Apr 1;23(10):2201-7 PMID: 15800312
  33. Oncologists' recommendations of clinical trial participation to patients.
    Patient Educ Couns. 2008 Jan;70(1):143-8 PMID: 17983722
Article Info
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abbr.
J Clin Oncol
ISSN
1527-7755
Published
2008-06-01
Pages
2666-73
Language
English
Region
United States
NLM ID
8309333
PMCID
PMC3807688
Subset
IM
Grants
NCI NIH HHS · P30 CA022453 · United States
NCI NIH HHS · R01 CA075003 · United States
NCI NIH HHS · R01 CA140314 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]